Showing all 3 results

3,490.00 Excl. VAT

BioPharmAnalyses and OctopusyX BioConsulting are proud to announce the launch of their up-dated and enriched 2019 edition of their report entitled « Landscape in Gene Therapy Companies » In this 800-pages report, a must-have read one, you will find -More than 230 closely scrutinized companies -More than 600 products identified including more than 200 products at the clinical stage -More than 300 VC or investors mentioned -Mor than 200 pathologies referred -A detailed Overview of Companies involved in AAV-based gene therapy, LV-based Gene Therapy, Gene Therapy, CDMO (Contracts, Manufacturing Organisation) and a Miscellaneous section including Hubs and Non Viral Gene Transfer) CAR-T strategies will be dealt separately in the updated edition of our Briefing on CAR-T clinical trials. The 2019 edition will be published next November For further information, alb@biopharmanalyses.fr or olivier@octopusyx.fr  

5,990.00 Excl. VAT

Gene therapy is a rapidly and obviously evolving field that is now definitively recognized as a well-acknowledged major medical and scientific area. OctopusyX BioConsulting and BioPharmAnalyses are proud to announce the launch of iheir new global commercial report “Landscape in Gene Therapy Companies“. This is the first such report that provides you with an actually updated information and an accurate international mapping [...]